Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brincidofovir in Relapsed or Refractory Lymphoma and ENKL
NCT06761677Phase 2Suspended
- Sponsor
- SymBio Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Oct 2027
- Modality
- Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of brincidofovir in lymphoma and Extranodal NK/T-cell lymphoma (ENKTL), sponsored by SymBio Pharmaceuticals. Primary endpoints: Dose Limiting Toxicity, Maximum Tolerated Dose, and Recommended Phase 2 Dose at 28 days and Preliminary Efficacy at 7 months. Started Jun 2025; status: suspended.
02
Drugs
brincidofovir
03
Conditions
lymphomaExtranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT06761677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06761677.